



© Sydney University

**Grenoble:
the Clineatec Endowment Fund is recruiting an
international researcher
to carry out work on
neurodegenerative diseases**

Based in Grenoble, the Clineatec Endowment Fund welcomes among its teams the Australian researcher John Mitrofanis, a neuroanatomist coming from the University of Sydney. He will be the head of the research centre in neurodegenerative diseases, FDD Clineatec. The arrival of John Mitrofanis marks a turning point for the Covéa NeuroTec project, starting with research work related to Alzheimer's disease.

John Mitrofanis is a specialist in the field of red to near-infrared technology (photobiomodulation) in the treatment of brain pathologies, in particular the neurodegenerative diseases, Alzheimer's and Parkinson's disease. He has worked previously at Clineatec, collaborating on many preclinical trials of this technology. These trials showed a clear neuroprotective effect of photobiomodulation in Parkinson's disease, and drew the attention of industry. This led subsequently to support for a clinical trial on the treatment.

After this first experience at Clineatec, John Mitrofanis joined the Clineatec Endowment Fund to extend its work. Today, the impact of photobiomodulation in other neurodegenerative pathologies is considerable and forms a major axis for further development. Parkinson's disease, but also Alzheimer's disease and macular degeneration in the retina ... so many pathologies that will become fields of development for photobiomodulation technology under the control of John Mitrofanis. Studies related to the understanding of the mechanisms behind the effects of photobiomodulation will also be at the centre of John Mitrofanis' research actions.

The arrival of John Mitrofanis within the Clineatec Endowment Fund also marks a new turning point for the Covéa NeuroTec project, a major patron of the FDD for several years. The Covéa NeuroTec programme has a global aim to show that photobiomodulation neuroprotects, or slows the progression of Alzheimer's disease. This is a major challenge for our society and patients, because this disease, that affects more than 900,000 people in France, currently remains without an effective therapeutic option.

"We are honoured to welcome Professor John Mitrofanis to lead a research hub on neurodegenerative diseases. His multiple experiences and in-depth knowledge in neuroscience will be a major asset in accelerating R&D, alongside sponsorship, in order to find satisfactory solutions for patients", comments Thierry Bosc, Director of the Clineatec Endowment Fund.

"As a leader in the field of property and liability insurance, it is our duty to support research to improve support for accident victims as part of their life project. In this respect, Clinattec is unique in its kind in France, bringing together researchers, engineers and doctors in a center of excellence. We are committed to their side and are full of hope and confidence for the start of the research program called Covéa NeuroTec ", Thierry Derez, Chairman and CEO of Covéa.

About the Clinattec Endowment Fund

The Clinattec Endowment Fund was created in 2014 to find external funds to support and finance the innovative projects of Clinattec (Edmond J. Safra Research Center). The Endowment Fund has launched a sponsorship campaign "Patients don't have time to be patient" with the aim of raising € 30 million. The Clinattec Endowment Fund is infinitely grateful to all of its patrons for their support. More information on the Research Center:

www.clinattec.fr

Clinattec, Edmond J Safra biomedical research center, was created by Professor Benabid, co-inventor of deep neurostimulation, a technology that stops the symptoms of Parkinson's disease. At Clinattec, micro-nanotechnologies and electronics are at the service of health and patients. Doctors, technologists, researchers and biologists aim, through technology, to better prevent, better diagnose and better treat neurodegenerative diseases, cancers, epilepsy and severe motor disabilities. A propos du Fonds de Dotation Clinattec

About Covéa

A French mutual insurance group, Covéa is a leader in damage and liability and protects one in three households thanks to its 21,000 employees in France, employed daily in the service of 11.6 million policyholders.

With its three brands MAAF, MMA and GMF, Covéa is a solid and dynamic financial player. The Covéa group is also present internationally. www.covea.eu

PRESS CONTACTS

Agence Epoka

Camille Le Hyaric – clehyaric@epoka.fr – 06 60 43 65 02